Schnitzler Syndrome
Schnitzler syndrome is a rare and complex autoinflammatory disorder defined by chronic urticaria together with an abnormal protein in the blood (a monoclonal gammopathy, usually IgM).
It remains a medical challenge, but at Haute-Derma we use the latest international diagnostic criteria to free patients from persistent rashes, and we set up careful monitoring to prevent long-term hematological complications. With the right treatment plan, patients can achieve complete remission and lead a normal life.
How We Diagnose Schnitzler Syndrome at Haute-Derma
Because the symptoms are easily mistaken for ordinary hives, Haute-Derma uses the Strasbourg criteria to confirm the diagnosis:
- Serum protein electrophoresis: Identifies a monoclonal component (usually IgM, rarely IgG), which is a mandatory criterion.
- Skin assessment: Pale pink urticarial papules that usually sting rather than itch and last 12–24 hours.
- Skin biopsy: Shows a perivascular neutrophilic infiltrate (neutrophilic urticarial dermatosis) without true vasculitis.
- Imaging (X-ray, CT or MRI): Looks for osteosclerosis, a characteristic finding in about 30–40% of patients.
- Inflammatory markers: CRP and blood neutrophil counts are monitored, as both rise during flares.
Our Approach to Schnitzler Syndrome
At Haute-Derma, our specialists treat this syndrome as a condition that sits at the crossroads of dermatology, immunology and hematology. Treating the visible hives alone is not enough; the systemic inflammation and the abnormal blood protein both need to be controlled.
Our team leads the way in using therapies that target interleukin-1 (IL-1), the key driver of Schnitzler symptoms. You can be confident that we will provide an accurate diagnostic pathway and the most advanced treatment available to protect your overall health.
Our Schnitzler care pathway includes:
- Precise identification of the monoclonal protein by serum protein electrophoresis.
- Rapid control of inflammation with modern biologic therapies.
- Long-term follow-up to detect early signs of malignant transformation, such as Waldenström macroglobulinemia or lymphoma.
How Is Schnitzler Syndrome Treated at Haute-Derma?
We use potent immunomodulating regimens to switch off the systemic inflammatory response:
- Interleukin-1 (IL-1) blockade: Drugs such as anakinra or canakinumab are considered a lifeline for people with Schnitzler syndrome. Most of our patients at Haute-Derma see their fever and rash disappear completely within hours to a few days of starting treatment.
- Colchicine or nonsteroidal anti-inflammatory drugs (NSAIDs): Help control bone and joint pain in milder disease.
- Systemic immunosuppressants: In some cases we consider cyclosporine or other biologic agents if a patient does not respond to standard therapy.
- Hematology monitoring program: The most important part of care at Haute-Derma. Patients have regular blood tests to track the monoclonal protein level, so any sign of progression to a malignant blood disorder is caught early.
